Skip to content
RNAWiki

Methyldopa

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Methyldopa does in the body

has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity.

From the FDA-approved label: Methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity. Methyldopa has been shown to cause a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine, and epinephrine.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · 56LH93261Y · read 2026-08-29

  • Its recorded molecular formula is C10H13NO4, weighing 238.24.

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-30

Where each sentence above came from

What the label states this substance does, quoted from it. No plain-language version of this sentence has been written.

No recorded use is stored in reader language.

No statement of the main limit is recorded.

The four opening statements run to 132 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Maternal or Perinatal death or morbidity

The study did not show it

Who was studied
NCT01911494
How many people
87500
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

change of estimated GFR calculated by MDRD equation and onset of microalbuminuria

The study did not show it

Who was studied
NCT01500590
How many people
1400
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Successful outcome

The study did not show it

Who was studied
NCT01912677
How many people
894
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Fugl-Meyer-Motor Assessment Score (FMMA)

The study did not show it

Who was studied
NCT03735901
How many people
610
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,

The study did not show it

Who was studied
NCT01568073
How many people
600
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)

The study did not show it

Who was studied
NCT01227655
How many people
427
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • & USAGE Hypertension.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “There are no well-controlled clinical trials in pediatric patients.”

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-30

  • On older people, the label states: “Of the total number of subjects (1,685) in clinical studies of methyldopa, 223 patients were 65 years of age and over, while 33 patients were 75 years of age and over.”

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-30

  • On people who are pregnant, the label states: “Reproduction studies performed with methyldopa at oral doses up to 1000 mg/kg in mice, 200 mg/kg in rabbits and 100 mg/kg in rats revealed no evidence of harm to the fetus.”

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-30

  • On people who are breastfeeding, the label states: “Therefore, caution should be exercised when methyldopa is given to a nursing woman.”

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

RNAWiki has not recorded a supervision or regulatory status for this substance.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

No register row and no identity class settled the question.

No source is stored against this line.

What is in the pack

Sold as tablet, suspension, tablet, film coated, given by the oral route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 6 products list this as an active ingredient in the United States drug directory. 6 of them contain it and nothing else.

    FDA National Drug Code directory · 62135-321 · read 2026-08-29

  • They are sold as powder, tablet and tablet, film coated, taken oral.

    FDA National Drug Code directory · 62135-321 · read 2026-08-29

  • The regulator's established pharmacologic class for it is adrenergic alpha2-agonists [moa] and central alpha-2 adrenergic agonist [epc].

    FDA National Drug Code directory · 62135-321 · read 2026-08-29

  • 2 published labels name it as an active ingredient. 2 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-29

  • 5 marketed supplement labels list this ingredient, classed as botanical, botanical with nutrients and other combinations.

    NIH Dietary Supplement Label Database · 204034 · read 2026-08-29

  • Those labels carry all other and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.

    NIH Dietary Supplement Label Database · 204034 · read 2026-08-29

  • Methyldopa is oral at HOW SUPPLIED Methyldopa Tablets, USP are supplied as film-coated tablets containing either 250 mg or 500 mg of Methyldopa, USP., recorded as fda label in effect 2025-03-28 in the United States.

    US prescribing information · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · read 2026-08-30

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.

Questions worth asking

  • Which of the trials of Methyldopa studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Methyldopa are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
56LH93261Y
RxNorm concept
197956

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Not passed

    Safety mode resolved

    No register row and no identity class settled the question.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 91 approved applications cover products containing this substance. The earliest was NDA013400, approved 19621220 to MERCK.

    Drugs@FDA application register · NDA013400 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA013400 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19840629.

    FDA National Drug Code directory · 62135-321 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (10)

On the Methyldopa label: indicated for what?

"INDICATIONS & USAGE Hypertension.": indications and usage on Methyldopa's label. DailyMed label · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · 2025-03-28

23 registered trials of Methyldopa — at which phases?

Registered studies posting no result
21 of 23

23 registered studies of Methyldopa: 9 phase4, 5 na, 5 phase2, 3 phase1, 1 na or unstated, 1 phase3. CLINICALTRIALS_SNAPSHOT · 2026-09-01

448 with a PubMed record

Show the evidence
  • phase4
    9
  • na
    5
  • phase2
    5
  • phase1
    3
  • na or unstated
    1
  • phase3
    1
6 more recorded rows
  • completed
    12
  • unknown
    5
  • withdrawn
    3
  • active not recruiting
    1
  • recruiting
    1
  • terminated
    1

recorded 2026-09-01 · last checked 2026-09-04

4 of Methyldopa's trials stopped: funding/business, other?

funding/business (2) and other (2): Methyldopa's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Lack of funding"; 4 of 23 registered studies

Show the evidence

Trial

  • NCT00194974
    withdrawn; "Lack of funding"
  • NCT00329511
    withdrawn; "Feasibility of study. PI termination"
  • NCT03152409
    terminated; "Inadequate resources to complete the study"
  • NCT03396484
    withdrawn; "Study not begun due to continued laboratory work on the feasibility of outcome measures."

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Methyldopa used BF-Methyldopa 250mg Tablet — over how long?

Human studies of Methyldopa used "BF-Methyldopa 250mg Tablet". ClinicalTrials.gov · 2026-09-01

7 recorded entries; human; also "Methyldopa 250mg Tablet", "Methyldopa 250 MG", "methyldopa tablets 250mg"

Show the evidence

human

  • NCT03210025
    BF-Methyldopa 250mg Tablet
  • NCT03210025
    Methyldopa 250mg Tablet
  • NCT04835233
    Methyldopa 250 MG
  • NCT05888896
    methyldopa tablets 250mg
  • NCT05888896
    methyldopa tablets 250mg + foot reflexology
  • NCT06618521
    Anti-hypertensive drug (Methyldopa 250 mg)
1 more recorded row
  • human NCT06618521
    Methyldopa 250 mg

recorded 2026-09-01 · last checked 2026-09-04

Methyldopa's half-life is 105 minutes — which schedules were studied?

105 minutes, the half-life Methyldopa's label states: "The plasma half-life of methyldopa is 105 minutes." DailyMed label · 9e22e1d8-04ec-4b67-92ea-b09c706f2703 · 2025-03-28

Show the evidence
  • half life clinical_pharmacology
    105 minutes; The plasma half-life of methyldopa is 105 minutes.
  • metabolism clinical_pharmacology
    Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission, and/or reduction of plasma renin activity.

recorded 2025-03-28 · last checked 2026-09-04

Which running trial of Methyldopa could settle lifespan?

NCT03079999 measures Progression Free Survival, reading out 2029-02.

1 open trial; n 97; "Study of Aspirin in Patients With Vestibular Schwannoma"

Show the evidence
  • Trial NCT03079999
    "Study of Aspirin in Patients With Vestibular Schwannoma"; n 97; "Progression Free Survival"; 2029-02

Which 10 trials of Methyldopa posted no result?

Posted no result
10 of 10 completed trials
Registrations
NCT00778193, NCT00966316, NCT03370848, NCT01674127, NCT00580619 and NCT03210025, and 4 more
Completion dates
oldest 2008-03; newest 2022-12-31
Show the evidence

Trial

  • NCT00778193
    2008-03
  • NCT00966316
    2011-01
  • NCT03370848
    2011-07
  • NCT01674127
    2012-05
  • NCT00580619
    2017-01
  • NCT03210025
    2017-10-15
4 further recorded trials
  • NCT01912677
    2017-12
  • NCT01911494
    2018-06
  • NCT04467931
    2020-12-31
  • NCT04835233
    2022-12-31

At the median, Methyldopa's trials enrolled 88 people — anything larger?

Median enrolment
88
Largest enrolment
87500
Registered trials counted
23

What do 1441 spontaneous reports say about Methyldopa — and not say?

These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Methyldopa appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1441 reaction mentions were counted: premature baby 437; premature delivery 270; low birth weight baby 210; atrial septal defect 99. FAERS via Open Targets · CHEMBL459 · 2026-06-24

Show the evidence
  • premature baby
    437
  • premature delivery
    270
  • low birth weight baby
    210
  • atrial septal defect
    99
  • foetal growth restriction
    95
  • caesarean section
    71
4 more recorded rows
  • pre-eclampsia
    71
  • hypertension
    71
  • patent ductus arteriosus
    60
  • small for dates baby
    57

recorded 2026-06-24 · last checked 2026-09-04

Which 10 reactions does Methyldopa's label not list?

atrial septal defect, caesarean section and foetal growth restriction and 7 more reported for Methyldopa, absent from its label. FAERS via Open Targets · CHEMBL459 · 2026-06-24

3 label terms; 10 reported and unlisted; 9e22e1d8-04ec-4b67-92ea-b09c706f2703

Show the evidence
  • atrial septal defect
    count not stated
  • caesarean section
    count not stated
  • foetal growth restriction
    count not stated
  • hypertension
    count not stated
  • low birth weight baby
    count not stated
  • patent ductus arteriosus
    count not stated
4 more recorded rows
  • pre-eclampsia
    count not stated
  • premature baby
    count not stated
  • premature delivery
    count not stated
  • small for dates baby
    count not stated

recorded 2026-06-24 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL459
PubChem CID
38853
CAS number
555-30-6
RxCUI
1545996
InChIKey
CJCSPKMFHVPWAR-JTQLQIEISA-N
Trade name
Aldomet, Dopamet, Dopegyt, Lederdopa, Medomet, Medopren, Metalpha 250, Metalpha 500, Methyldopa component of aldoril, Presinol
Also called
(-)-.alpha.-methyldopa, .alpha.-methyl-l-dopa, L-.alpha.-methyldopa, Metildopa, ALDORIL COMPONENT METHYLDOPA, L-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE SESQUIHYDRATE, L-TYROSINE, 3-HYDROXY-.ALPHA.-METHYL-, SESQUIHYDRATE, METHYLDOPA HYDRATE [JAN], METHYLDOPA SESQUIHYDRATE [MART.], METHYLDOPA SESQUIHYDRATE [MI]
Salt form
Anhydrous methyldopa, Methyldopa anhydrous, Methyldopa hydrate, Methyldopa sesquihydrate
Development code
BAYER-1440L, J9.247I, MK-351, NSC-169916, NSC-760080
Sources (6)

Sources

ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.